EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Treatment selection for adenomyosis based on imaging findings and patient characteristics

Hiroshi Kobayashi iD

International Journal of Gynecology & Obstetrics · 2026

DOI: 10.1002/ijgo.70992 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Gynecology & Obstetrics, 2026. Verfasst von Hiroshi Kobayashi. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Nara Medical University, Kashihara, Japan. Hauptthemen laut MEDLINE: Adenomyosis. Die Arbeit nennt 60 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Adenomyosis is an estrogen‐dependent disorder characterized by substantial heterogeneity in lesion distribution, symptom presentation, disease severity, and reproductive impact, which limits the effectiveness of uniform treatment strategies. To summarize recent evidence on pharmacological and minimally invasive treatments for adenomyosis and to propose a clinically practical framework for treatment selection based on magnetic resonance imaging (MRI)‐based lesion subtypes, symptom phenotypes, disease severity, and reproductive intentions. A narrative review of recent literature was conducted focusing on hormonal therapies, gonadotropin‐releasing hormone (GnRH) antagonists, the levonorgestrel‐releasing intrauterine system (LNG‐IUS), dienogest, and minimally invasive treatments such as high‐intensity focused ultrasound (HIFU) and endometrial ablation. Outcomes were evaluated in relation to MRI‐based lesion localization, predominant symptoms, uterine size, and fertility preservation goals. Pharmacological therapy remains the cornerstone of conservative management. Sequential strategies using short‐term GnRH antagonists followed by maintenance therapy have been explored, although robust evidence is limited. LNG‐IUS and dienogest are commonly selected according to bleeding‐ or pain‐dominant symptoms and MRI‐based lesion subtypes, but interindividual variability in treatment response persists. Minimally invasive treatments show favorable outcomes mainly in localized disease, whereas efficacy in diffuse adenomyosis remains inconsistent. Treatment strategies differ according to reproductive intentions, with time‐limited interventions being central in fertility‐preserving management. Treatment of adenomyosis should move beyond a uniform approach toward individualized strategies integrating imaging findings and patient characteristics. An MRI‐based framework may support more rational and effective clinical decision making.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AdenomyosisHumansFemaleMagnetic Resonance ImagingGonadotropin-Releasing HormoneHormone AntagonistsLevonorgestrelNandroloneEndometrial Ablation TechniquesIntrauterine Devices, MedicatedHigh-Intensity Focused Ultrasound Ablation

Stichwörter der Autor:innen

adenomyosismagnetic resonance imagingminimally invasive treatmentpersonalized medicinepharmacological treatment

Substanzen

Gonadotropin-Releasing HormoneHormone AntagonistsLevonorgestreldienogestNandrolone

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, Nara Medical University, Kashihara, Japan.
  • Department of Gynecology and Reproductive Medicine, Ms.Clinic MayOne, Kashihara, Japan.

ORCID-Profile: Hiroshi Kobayashi

Zitieren

APA

Kobayashi, H. (2026). Treatment selection for adenomyosis based on imaging findings and patient characteristics. International Journal of Gynecology & Obstetrics. https://doi.org/10.1002/ijgo.70992

Vancouver

Kobayashi H. Treatment selection for adenomyosis based on imaging findings and patient characteristics. International Journal of Gynecology & Obstetrics. 2026. doi:10.1002/ijgo.70992

BibTeX
@article{Kobayashi2026,
  author = {Kobayashi, Hiroshi},
  title = {Treatment selection for adenomyosis based on imaging findings and patient characteristics},
  journal = {International Journal of Gynecology & Obstetrics},
  year = {2026},
  doi = {10.1002/ijgo.70992}
}
Kostenlos starten →